TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Validity of A Novel Computer Based Battery of Assessments in the Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and woman between the ages of 60-85, inclusive~* Cognitive function/impairment within appropriate ranges for the study (Mini-Mental State Exam scores of 10-30, inclusive)~Exclusion Criteria:~* Unable to complete computerized and standard pencil-and-paper based assessments

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- All participants (Type: None): All participants, including control, mild cognitive impairment, and dementia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \> or = 12 years of age~* NDD-CKD subjects~* Baseline hemoglobin \< or = 11g/dl~* Stable erythropoietin (EPO) status~Exclusion Criteria:~* Known hypersensitivity to ferrous sulfate or IV iron~* Unstable EPO status~* Anemia not related to CKD~* Chronic, serious infection~* Recent IV iron~* Recent blood transfusion~* Recent blood loss~* Need for surgery~* Received investigational drug within 30 days~* Female subjects who are pregnant or lactating

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
- Ferrous Sulfate tablets (Type: ACTIVE_COMPARATOR): 325 mg/TID x 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Written informed consent prior to participation~2. Female and male patients = 40 years of age~3. Patients diagnosed with COPD and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and COPD GOLD guideline recommendation~Exclusion criteria:~1. Patients with contraindications according to Spiolto® Respimat® SmPC~2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months~3. Patients continuing LABA- Inhalative Corticosteroides (iCS)treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks~5. Pregnancy and lactation~6. Patients currently listed for lung transplantation~7. Current participation in any clinical trial or any other non-interventional study of a drug or device

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto Respimat (Type: None): COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and females aged 40-75 years with COPD and symptoms such as cough, sputum production, and shortness of breath.~* Smoking history of at least 10 pack years~* FEV1 less than 65% of the predicted normal value and at least 0.75 L~* Pre-bronchodilator FEV1/FVC less than 70%~Exclusion Criteria:~* A history of asthma or COPD diagnosis before the age of 40~* Hospitalization for COPD exacerbation within the previous 6 weeks~* Respiratory tract infection within 6 weeks~* Use of long-term oxygen therapy~* Diabetes type I or uncontrolled diabetes type II~* Clinically relevant laboratory abnormality or clinically significant condition~* Corrected QT interval (QTc) above 430 ms for males and 450 ms for females, or a history of QTc prolongation. Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected adults (\<17 y.o.)~2. Antiretroviral-naïve.~3. Be able to comply with protocol requirements and instructions.~4. Subject or the subject's representative capable of giving signed informed consent.~Exclusion Criteria:~1. Women who are breastfeeding or plan to become pregnant during the study.~2. Patients who in the investigator's judgment, poses a significant drop out risk or life expectancy inferior to study ending.~3. Patients with anticipated need to change the ART before study ending.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIV-1 ART-Naive (Type: None): Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has histologically or cytologically-confirmed breast cancer~* Patient has documented skeletal metastases~Exclusion Criteria:~* Patient is undergoing current oral bisphosphonate therapy, or has a history of oral bisphosphonate use within 6 months of entry into study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single IV infusion of ZA 4 mg (Type: ACTIVE_COMPARATOR): Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
- Odanacatib 5 mg (Type: EXPERIMENTAL): Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have signed Informed Consent Form prior to initiation of any study-related procedure.~* Male and female adults aged ≥ 40 years.~* Patients with moderate to severe airflow obstruction with stable COPD (Stage 2 or Stage 3) according to the 2014 GOLD Guidelines.~* Patients with a post-bronchodilator FEV1 ≥40 and \< 80% of the predicted normal value, and post-bronchodilator FEV1/FVC \< 0.70 at run-in Visit 101. (Post refers to 15 min after inhalation of 400 µg of salbutamol).~* Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack /day x 10 years, or ½ pack/day x 20 years). An ex-smoker is defined as a patient who has not smoked for ≥ 6 months at screening.~* Patients who are on triple treatment at least for the last 6 months (LAMA +LABA/ICS).~Exclusion Criteria:~* Patients who have not achieved acceptable spirometry results at Visit 101 in accordance with ATS (American Thoracic Society)/ERS (European Respiratory Society) criteria for acceptability (one retest may be performed for patients that don't meet the acceptability criteria) .~* Patients who have had more than one COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the last year prior to Visit 1.~* Patients who developed a COPD exacerbation of any severity either 6 weeks before the screening (Visit 1) or between screening (Visit 1) and treatment (Visit 201) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): None
- Tiotropium + salmeterol/fluticasone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Standard rapi̇d Sequential Intubation Protocol With Rocuronium in Emergency Department

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be over the age of 18~* Need for advanced airway~* To give consent or consent to participate in the study consent of relatives of those who are unable to give~Exclusion Criteria:~* Have an indication of a crush (rescue) airway~* Have one of the difficult airway predictor Look, Evaluate, Obstruction, Neck mobility criteria~* maxillofacial anomaly or trauma~* detected during laryngoscopy with a cormack-lehane score of 3 and 4 patients~* Those who have inconveniences in applying ketamine to the clinic of the patient~* with a rocuronium or ketamine allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- standard (Type: None): standard rapid sequence intubation group (paralysis following induction)
- priming (Type: None): group primed with rocuronium before induction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically verified primary central nervous system lymphoma No prior PCNSL treatment.~* Patients treated with steroids alone are eligible~* No signs of lymphoma outside the CNS~* ECOG performance status 0-4~* Age \> 17 and \< 76 years~* Written informed consent from the patient or guardian~Exclusion Criteria:~* Cardiac failure \> 3~* Pregnancy or lactation. Women of childbearing potential are requested to use an effective method of contraception to avoid pregnancy for a period from entry to the study and at least 3 months after the last study medication~* Previous malignancy unless disease free for at least five years~* Active infection.~* Regarding tuberculosis, patients at risk should be tested for latent TB according local practice at each treating centre.~* Positive HIV status~* Organ transplantation~* Serious psychiatric illness~* Prior radiotherapy to the brain~* Concomitant anti-inflammatory medication that cannot be discontinued~* Creatinine clearance \< 60 ml/minute calculated by Cockcroft and Gault formula~* Peripheral blood count with granulocytes \<1.5 x 109L or platelets \< 100 x 109L~* Serum bilirubin \>1.5 times or ASAT and alkaline phosphatase \>2 times upper limits of normal.~* Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any component of Rituximab excludes patients from Rituximab treatment, but not from the remaining part of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* subject has provided informed consent~* Male or Female who require Long Length Imaging~Exclusion Criteria:~* Not able or willing to provide Informed Consent, or consent is withdrawn~* Not able to collect all required case information~* Patients who are unable to stand~* Images which are not clinically acceptable to the user~* Images without a reference object such as a ruler in the image.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pred. & Invest.-All Study Participants (Type: None): Cedera AccuStitch Software is standard of care software currently used at sites.~Carestream DR LLI software is investigational software used for reconstruction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Silver Modified and Conventional Atraumatic Restorative Treatment Modalities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Medically free children.~2. Clinical examination revealing at least one second primary molar with single surface active dentine carious lesions.~3. Children who agreed to participate and whose parents signed an informed consent.~4. Cooperative or potentially cooperative children according to Wright Classification~Exclusion Criteria:~1. Children who have known allergies to silver products.~2. Children with special health care needs or any medical conditions.~3. Children with designated molars having more than one third of their crown missing.~4. Children with designated molars showing signs of pulpal pathology such as spontaneous pain, presence of an abscess or sinus or mobility.~5. Children with designated molars having an existing restoration.~6. Children with designated molars having deep carious lesions with close proximity to the pulp.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- SMART (Type: EXPERIMENTAL): Silver modified atraumatic restorative treatment group in which advantage Arrest Silver diamine Fluoride 38% (Elevate oral Care, USA ) will be applied to carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
- Conventional ART (Type: ACTIVE_COMPARATOR): Conventional atraumatic restorative treatment group in which a sharp excavator will be used to remove caries from carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurophysiology of Prophylactic Treatment in Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (migraineurs):~* episodic migraine according to ICHD (international classification of headache disorders)-3 criteria~* headache documented over at least 3 months through a headache calender~* scheduled for prophylactic therapy of their migraine~Exclusion Criteria (migraineurs):~* history of chronic migraine~* current medication-overuse headache~* neurological or psychiatric diagnosis other than headaches~* chronic intake of central nervous system active drugs (antidepressants, antipsychotics etc.)~* contraindications for magnetic resonance imaging~* contraindications for transcranial magnetic stimulation~Inclusion criteria (controls):~* not more than 3 years younger or older than matched control~* gender similar to matched control~* menstrual cycle equal to matched control (if female)~exclusion criteria (controls):~* more than 1 headache day/month~* history of migraine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Episodic Migraine (Type: None): None
- Healthy controls (Type: None): equal to or less than 1 headache day/month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presents to the Emergency Department (ED) and meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)~* Known or suspected gram-positive infection.~Exclusion Criteria:~* Known or suspected gram-negative infections, anaerobic infections, or fungemia~* Known or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance~* Injection drug users with a fever~* Severe neurological disorder leading to immobility or confined to a wheelchair~* Bilateral Lower extremity involvement of the suspected infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: ACTIVE_COMPARATOR): Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
- New Critical Pathway (Type: ACTIVE_COMPARATOR): The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. the age of 18-75 years, female patients;~2. the diagnosis of breast cancer by biopsy;~3. participants voluntarily participated in the clinical trial and signed informed consent.~Exclusion Criteria:~1. had received SLNB or axillary surgery;~2. breast area radiotherapy or neoadjuvant chemotherapy has been accepted.~3. clinical hints of axillary lymph node metastasis;~4. discovery of distant metastasis;~5. inflammatory breast cancer;~6. women in pregnancy;~7. people with iodine allergy;~8. the serum creatinine was \> 1.5 times as high as the upper limit of the normal value.~9. to participate in clinical trials of other devices or drugs within one month;~10. the researchers consider it inappropriate to participate in this clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Self control (Type: EXPERIMENTAL): During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete